Your lung cancer treatment plan should be as unique as you are. Find out how your tumor's biomarkers help determine the best path forward. Learn more about PD-L1

Photos of Dr Schneider and Dr Mayer

Next-Gen Breakthroughs

New Researchers. New Possibilities.

LCFA welcomes two exceptional early career scientists to our research family. And the future of lung cancer care just got brighter.

Get to know them

Meet people living with lung cancer, thanks to research

More Stories

Recently diagnosed with lung cancer?

Learn more about your lung cancer diagnosis. What questions should you be asking? What are the most important next steps? Know that you have options and remember that knowledge is power.

We're here to help

Meet the Researchers

View All

  • Zhen Zeng, PhD

    Oncology

    Mapping exactly where cancer-fighting cells are located within tumors

    Zhen Zeng headshot

  • Jonathan Villena-Vargas, MD

    Thoracic Surgeon

    Characterizing T cell PD-1 response in the tumor-draining lymph nodes of early-stage NSCLC patients

  • Kellie Smith, PhD

    Leading an immunology lab in transformative cancer research

    Immunotherapy in Early Stage Lung Cancer

Stay Connected

Hope, Research, and Impact in Your Inbox

Join our community and receive monthly updates on inspiring stories, groundbreaking research, and the early career researchers you’re helping to support. Sign up now to be part of the lung cancer fight!

This field is for validation purposes and should be left unchanged.
Name(Required)

  • Research is HOPE. Research will hopefully have me sitting here in #GiveMe20. Give me 20 years post-diagnosis.

    Brandi Bryant, living with lung cancer

  • Your generosity is shaping future leaders in lung cancer research.

    Kim Norris, Co-Founder and President

  • There is such tremendous hope for all patients with lung cancer right now.

    Dr. Christine Lovly, LCFA Young Investigator

    View all

    Word of the Day

    EXON 21 L858R

    EXON 21 L858R is a specific mutation in the EGFR gene that can occur in non-small cell lung cancer (NSCLC). It is one of the most common EGFR mutations and can be targeted with specific therapies known as EGFR inhibitors.